Sarepta Therapeutics (NASDAQ:SRPT) will host a webcast and conference call on Monday, June 8, at 8:30 am ET to present new data from six-subject Phase 1/2 clinical trial evaluating gene therapy candidate SRP-9003 in patients with beta-sarcoglycanopathy or Limb-girdle muscular dystrophy type 2E, a rare type of muscular dystrophy characterized by weakness in the pelvic and shoulder girdle.
Results will include expression and safety data
from the high-dose cohort and one-year functional results from the
low-dose cohort.
https://seekingalpha.com/news/3580895-sarepta-to-release-data-on-gene-therapy-for-rare-type-of-muscular-dystrophy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.